Free Trial
NASDAQ:OPTN

OptiNose Q1 2025 Earnings Report

OptiNose logo
$9.51 -0.01 (-0.09%)
As of 11:00 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OptiNose EPS Results

Actual EPS
-$1.01
Consensus EPS
-$0.74
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

OptiNose Revenue Results

Actual Revenue
$18.51 million
Expected Revenue
$17.70 million
Beat/Miss
Beat by +$810.00 thousand
YoY Revenue Growth
N/A

OptiNose Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

OptiNose Earnings Headlines

How much money will YOU make when gold hits $5,000?
What if I told you there was a way to secure a shot at making asymmetric gains from gold’s current historic bull market run. Investors who choose to follow his lead could have the chance to bring home gains as high as 2,066%.
Optinose reports Q4 EPS (3c) vs ($1.33) last year
See More OptiNose Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OptiNose? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OptiNose and other key companies, straight to your email.

About OptiNose

OptiNose (NASDAQ:OPTN), a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

View OptiNose Profile

More Earnings Resources from MarketBeat